FibroBiologics (FBLG) Net Income towards Common Stockholders (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Net Income towards Common Stockholders of -$5.6 million for Q2 2026, down 19.36% year-over-year from -$6.9 million in Q2 2025, and up 26.44% on a QoQ basis from -$7.6 million in Q1 2026.
FibroBiologics (FBLG) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
FibroBiologics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$5.6 million in Q2 2026.
- Net Income towards Common Stockholders for Q2 2026 came in at -$5.6 million, down 19.36% year-over-year; the trailing twelve-month figure through Jun 2026 was -$23.7 million (down 79.6% YoY), and the FY2025 annual result was -$25.6 million, down 129.67% from the prior year.
- Net Income towards Common Stockholders rose to -$5.6 million in Q2 2026, from -$7.6 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $898000.0 in Q2 2024 and troughed at -$9.7 million in Q4 2023.
- A 4-year average of -$4.5 million and a median of -$4.8 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders surged 141.57%; it then tumbled 1473.2% in 2025.
- A 4-year view of Net Income towards Common Stockholders shows it stood at -$9.7 million in 2023, then jumped by 68.11% to -$3.1 million in 2024, then gained by 10.81% to -$2.8 million in 2025, then tumbled by 101.16% to -$5.6 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$5.6 million in Q2 2026, -$7.6 million in Q1 2026, and -$2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.56 Mn |
| Mar 31, 2026 | -7.56 Mn |
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -7.87 Mn |
| Jun 30, 2025 | -4.66 Mn |
| Mar 31, 2025 | -4.97 Mn |
| Dec 31, 2024 | -3.10 Mn |
| Sep 30, 2024 | -500,000.00 |
| Jun 30, 2024 | 898,000.00 |
| Mar 31, 2024 | -8.46 Mn |
| Dec 31, 2023 | -9.72 Mn |
| Sep 30, 2023 | -2.19 Mn |
| Jun 30, 2023 | -2.16 Mn |
| Mar 31, 2023 | -4.99 Mn |